leadf
logo-loader
viewAdamas Finance Asia Limited

Adamas Finance Asia to invest in developer of needle-free injection technology

Suresh Withana from Harmony Capital, the investment manager of Adamas Finance Asia Limited (LON:ADAM), tells Proactive London's Andrew Scott they're planning to invest up to US$5mln into the developer of needle-free injection technology.

PharmaJet Inc’s innovative technology has received US Food & Drug Administration marketing clearance, is CE-Marked in Europe and is PQS certified by the World Health Organisation.

Quick facts: Adamas Finance Asia Limited

Price: 24.5 GBX

AIM:ADAM
Market: AIM
Market Cap: £25.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adamas Finance Asia Limited named herein, including the promotion by the Company of Adamas Finance Asia Limited in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Adamas Finance Asia reveals 'exciting' updates on two portfolio companies in...

Suresh Withana from Harmony Capital Investors, the adviser to Adamas Finance Asia Limited (LON:ADAM) gives Proactive an update on two of its portfolio companies. Withana says wind turbine design and wind turbine blade manufacturing company Meize Energy Industries Holdings in China has opened a...

on 17/8/20

2 min read